ArticleStem cell research & therapy2016
Intraperitoneally infused human mesenchymal stem cells form aggregates with mouse immune cells and attach to peritoneal organs.
Article in Stem cell research & therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 90 citations in OpenAlex.
- High-Resolution 3D Bioprinted Hydrogel Scaffolds Enable Sustained Intraperitoneal Cell Delivery.Molecules (Basel, Switzerland) · 2026Article
- Article
- Advances in mesenchymal stem cell therapy for lupus nephritis.World journal of stem cells · 2025Review
- Combining sodium-glucose co-transporter-2 inhibitor with mesenchymal stem cells and brown adipose tissue (BAT) and white adipose tissue (WAT) transplantation to mitigate the progression of diabetic kidney disease: a pre-clinical approach.Stem cell research & therapy · 2025Article
- Neuroprotection of Stem Cells Against Ischemic Brain Injury: From Bench to Clinic.Translational stroke research · 2024Review
- Astragalus polysaccharides augment BMSC homing via SDF-1/CXCR4 modulation: a novel approach to counteract peritoneal mesenchymal transformation and fibrosis.BMC complementary medicine and therapies · 2024Article
- Mesenchymal stem cells derived from CHIR99021 and TGF‑β induction remained on the colicomentum and improved cardiac function of a rat model of acute myocardium infarction.Experimental and therapeutic medicine · 2024Article
- Bone marrow stromal cell-derived hepcidin has antimicrobial and immunomodulatory activities.Scientific reports · 2024Article
- Mesenchymal stromal cells (MSCs) as a therapeutic agent of inflammatory disease and infectious COVID-19 virus: live or dead mesenchymal?Molecular biology reports · 2024Review
- Article
- Different priming strategies improve distinct therapeutic capabilities of mesenchymal stromal/stem cells: Potential implications for their clinical use.World journal of stem cells · 2023Review
- Definitive Endodermal Cells Supply an in vitro Source of Mesenchymal Stem/Stromal Cells.Communications biology · 2023Article
- MHC Class I Enables MSCs to Evade NK-Cell-Mediated Cytotoxicity and Exert Immunosuppressive Activity.Stem cells (Dayton, Ohio) · 2022Article
- How mesenchymal stem cell cotransplantation with hematopoietic stem cells can improve engraftment in animal models.World journal of stem cells · 2022Article
- Human Amniotic Fluid Stem Cells Ameliorate Thioglycollate-Induced Peritonitis by Increasing Tregs in Mice.International journal of molecular sciences · 2022Article
- Mechanism of Action of Mesenchymal Stem Cells (MSCs): impact of delivery method.Expert opinion on biological therapy · 2022Article
- Secondary Lymphoid Organs in Mesenchymal Stromal Cell Therapy: More Than Just a Filter.Frontiers in immunology · 2022Review
- Immunomodulatory Activity of Mesenchymal Stem Cells in Lupus Nephritis: Advances and Applications.Frontiers in immunology · 2022Review
- Safety and Homing of Human Dental Pulp Stromal Cells in Head and Neck Cancer.Stem cell reviews and reports · 2021Article
- Cell therapy and delivery strategies for spinal cord injury.Histology and histopathology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundMesenchymal stem/progenitor cells (MSC) have shown beneficial effects in many models of disease in part by modulating excessive inflammatory and immune responses. Frequently the beneficial effects of MSC persist long after their disappearance from host tissues, suggesting that MSC interact with intermediate cells in the host that relay or amplify their effects. The cells have usually been injected intravenously, but beneficial effects have also been reported with intraperitoneal (IP) injection of MSC. However the fate of IP injection of MSC has not been examined.
methodsThe fate of the human MSC injected IP into immune-competent mice was studied. In vivo imaging was used to track green fluorescent protein-labeled MSC in the peritoneal cavity. In addition, their retention in peritoneal tissues was measured by real-time polymerase chain reaction for human GAPDH mRNA. To describe the effects of human MSC on the immune system of the peritoneum, the peritoneal lavage, omentum, lymph nodes and mesenteric tissues were collected. Flow cytometry was used to evaluate the immune cell populations, while cytokine/chemokine production was measured by real-time polymerase chain reaction and enzyme-linked immunosorbent assay. Challenge with lipopolysaccharide at 3 days after the administration of MSC was used to evaluate the preconditioning of the immune system.
resultsWithin 20 min, single MSC were no longer detected in peritoneal lavage fluid. Instead they were recovered as aggregates of varying size that contained mouse macrophages and a few B220+ lymphocytes. After 1 day, most of the aggregates containing live MSC were attached to sites throughout the peritoneal cavity including the omentum and mesentery. Less than 0.05 % of the live injected cells were detected in the spleen and jejunal lymph nodes. In all locations, MSC colocalized with mouse macrophages and B220+ lymphocytes. Attachment to the omentum and mesentery was accompanied by the recruitment of immune cells and changes in the production of a series of mouse cytokines. A similar increase in mouse cytokines in the peritoneum was seen after IP injections of human fibroblasts.
conclusionsIP injected human MSC rapidly formed aggregates with mouse macrophages and B220+ lymphocytes and attached to the walls of the peritoneal cavity. The formation of the aggregates probably limits access of the cells to the systemic circulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.